Your session is about to expire
← Back to Search
CAR T Cell Immunotherapy for Pancreatic Cancer
Study Summary
This trial is testing a new cancer treatment on patients with pancreatic cancer that has spread or can't be removed with surgery.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I need extra oxygen to help me breathe.I have had treatment with gene-modified cells before.I have an active cancer that is not pancreatic adenocarcinoma.I rely on steroids or immunosuppressant drugs for my health.I have fluid buildup that can't be drained with usual methods.I have tried at least one standard chemotherapy for my advanced disease.My advanced disease has not worsened on first-line chemotherapy.I am 18 years old or older.I am fully active or restricted in physically strenuous activity but can do light work.My organs and bone marrow are functioning well.I do not have severe lung disease.I have fluid in my abdomen or disease on my peritoneum confirmed by tests.I have inoperable or spread pancreatic cancer.I haven't taken immunosuppressants for my autoimmune disease in the last 4 weeks.My cancer has spread to my liver.I have serious heart fluid buildup or heart conditions.I currently have an infection.I am HIV positive.
- Group 1: Cohort -1: low dose huCART-meso cells via intravenous infusion
- Group 2: Cohort 1: huCART-meso cells via intravenous infusion (IV).
- Group 3: Cohort 3 - huCART meso cells via intrahepatic infusion (hepatic arterial infusion)
- Group 4: Cohort 4 - huCART meso cells via intrahepatic infusion (hepatic arterial infusion)
- Group 5: Cohort 2 - huCART meso cells via intraperitoneal infusion (IP)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are any slots available for enrollment in this experiment?
"Based on documentation hosted on clinicaltrials.gov, this scientific investigation is presently enrolling participants. This research project was initially advertised in September 2017 and the most recent update was from August 2022."
Are there any risks associated with huCART-meso cell treatments?
"The potential risks associated with huCART-meso cells have been minimally assessed, leading our team at Power to rate its safety a 1 on the scale of 1–3."
To what extent has recruitment for this research been completed?
"Affirmative. According to the information hosted on clinicaltrials.gov, this medical experiment is currently in need of participants and was initially posted on September 15th 2017. 18 volunteers are sought from 1 primary site."
Share this study with friends
Copy Link
Messenger